ABBOTT LABORATORI…
USUSDABBOTT LABORATORIES (XETRA:ABL) — Biotechnology: Pharmaceutical Preparations. Numero di borse in cui sono quotate le azioni della società: 4. In questa pagina: prezzo e grafico, dividendi, principali azionisti e cronologia del numero di azioni.
Informazioni sull'Azienda
- Sito Web
- abbott.com
- Settore
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sede Centrale
- North Chicago, United States
- Amministratore Delegato
- Robert Ford
- Dipendenti
- 73 000
- Fondata
- 1888
- Quotata dal
- 20.12.2007 (XETRA:ABL)
- Azioni in Circolazione
- 1.73 Mld al 2026-06-30
- Flottante
- 1.72 Mld
- Capitalizzazione di Mercato
- 169.83 Mld USD
- Insider
- 0.49%
- Investitori Istituzionali
- 81.79%
- Settore (SIC)
- Pharmaceutical Preparations
- Forma Giuridica
- AZUK
- ISIN
- US0028241000
- LEI
- HQD377W2YR662HK5JX27
- P/E
- 33.4
- Payout Ratio
- 66.7%
- FCF
- 7.38 Mld USD
- Pagamenti / FCF
- 57%
- Debito
- 34.0 Mld USD3.7 anni di FCF
- Serie di Dividendi
- 43 a.
- Utili, FCF e dividendi pagati — per i 12 mesi fino a 31.03.2026 (l'ultimo rapporto dell'azienda).
- NAV
Descrizione
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, hypertriglyceridemia, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also provides laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion serology testing; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; and drug and alcohol test. In addition, the company offers pediatric and adult nutritional products and infant formula; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices. The company was formerly known as Abbott Alkaloidal Company and changed its name to Abbott Laboratories in 1915. Abbott Laboratories was founded in 1888 and is based in Abbott Park, Illinois.
Dividendi
ABBOTT LABORATORIES (ABL) paga dividendi trimestralmente. All'anno (12 mesi fino all'ultimo pagamento annunciato): 1.6798 EUR per azione (pagamenti: 3). Questo rappresenta circa il 1.89% del prezzo attuale delle azioni. In base alla storia dei pagamenti, la prossima data ex-dividendo è prevista intorno al 13.01.2027. Storia dei dividendi ininterrotta: 43 anni.
| Data Ex | Pagamento | Importo | % | Tipo | Ticker |
|---|---|---|---|---|---|
| 2026-07-15 | — | 0.5599 EUR | 0.7/2.8 % | trimestrale | XETRA:ABL |
| 2026-04-15 | — | 0.5599 EUR | 0.6/2.5 % | trimestrale | XETRA:ABL |
| 2026-01-15 | — | 0.5599 EUR | 0.5/2.0 % | trimestrale | XETRA:ABL |
| 2025-10-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2025-07-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2025-04-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2025-01-15 | — | 0.5244 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2024-10-15 | — | 0.4888 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2024-07-15 | — | 0.4888 EUR | 0.5/2.0 % | trimestrale | XETRA:ABL |
| 2024-04-12 | — | 0.4888 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2024-01-11 | — | 0.4888 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2023-10-12 | — | 0.4533 EUR | 0.5/2.0 % | trimestrale | XETRA:ABL |
| 2023-07-13 | — | 0.4533 EUR | 0.5/1.8 % | trimestrale | XETRA:ABL |
| 2023-04-13 | — | 0.4533 EUR | 0.5/1.9 % | trimestrale | XETRA:ABL |
| 2023-01-12 | — | 0.4533 EUR | 0.4/1.6 % | trimestrale | XETRA:ABL |
| 2022-10-13 | — | 0.4177 EUR | 0.4/1.6 % | trimestrale | XETRA:ABL |
| 2022-07-14 | — | 0.4177 EUR | 0.4/1.2 % | trimestrale | XETRA:ABL |
| 2022-04-13 | — | 0.4177 EUR | 0.4/0.8 % | trimestrale | XETRA:ABL |
| 2022-01-13 | — | 0.4177 EUR | 0.4/0.4 % | trimestrale | XETRA:ABL |
Notizie di Questa Settimana
Comunicati stampa dal sito web per investitori della società, aggiornati quotidianamente. I link conducono al sito web dell'azienda. I titoli sono nella lingua originale, come sul sito web dell'azienda.
| 13.10.2026 | Newsroom | Top Stories |
| 12.10.2026 | Newsroom | Top Stories |
Principali Azionisti
| Detentore | Quota | Azioni | Data del Rapporto |
|---|---|---|---|
| BlackRock | 8.82% | 152.56 Mln | 2026-06-30 |
| Vanguard Capital Managem… | 6.57% | 113.75 Mln | 2026-06-30 |
| State Street Corporation | 4.68% | 80.93 Mln | 2026-06-30 |
| Charles Schwab Investmen… | 3.45% | 59.67 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.2% | 55.3 Mln | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.83% | 49.02 Mln | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.61% | 45.14 Mln | 2026-06-30 |
| Geode Capital Management… | 2.27% | 39.22 Mln | 2026-06-30 |
| Capital Research Global… | 2.13% | 36.91 Mln | 2026-06-30 |
| Capital International In… | 2% | 34.65 Mln | 2026-06-30 |
| SCHWAB STRATEGIC TRUST-S… | 1.9% | 32.82 Mln | 2026-05-31 |
| Morgan Stanley | 1.54% | 26.61 Mln | 2026-06-30 |
| NORGES BANK | 1.35% | 23.35 Mln | 2026-06-30 |
| iShares Trust-iShares Co… | 1.34% | 23.2 Mln | 2026-08-31 |
| Fidelity Concord Street… | 1.3% | 22.52 Mln | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.23% | 21.31 Mln | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.01% | 17.53 Mln | 2026-07-31 |
| VANGUARD INDEX FUNDS-Van… | 0.96% | 16.58 Mln | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.52 Mln | 2026-08-31 |
| Investment Co of America | 0.6% | 10.33 Mln | 2026-06-30 |
| STARKS DANIEL J (Directo… | ≈0.39% | 6.75 Mln | 2026-04-27 |
| FORD ROBERT B. (Chief Ex… | ≈0.03% | 522 664 | 2026-08-25 |
| ALLEN HUBERT L. (Officer… | ≈0.01% | 200 281 | 2025-02-25 |
| SALVADORI DANIEL GESUA S… | ≈0.01% | 146 377 | 2026-03-02 |
| CONROY KEVIN T (Director… | ≈0.01% | 133 737 | 2026-04-24 |
| MORELAND MARY K (Officer… | ≈0.01% | 116 136 | 2026-03-02 |
| EARNHARDT LISA D (Office… | ≈0.01% | 98 984 | 2026-02-24 |
| SCOGGINS CHRISTOPHER J (… | ≈0% | 82 123 | 2026-02-24 |
| WAINER ANDREA F (Officer… | ≈0% | 74 381 | 2025-03-03 |
| The Vanguard Group | — | — | — |
| BOUDREAU PHILIP P (Chief… | — | — | 2026-04-23 |
